Norbert Bischofberger (Kronos Bio Inc. (Nasdaq: KRON))

Bischofberger, Norbert (Kronos Bio 202010 CEO before Gilead Sciences 200903 EVP R&D CSO)

	Organisation	Gilead Sciences Inc. (Nasdaq: GILD)
	Group	Gilead Sciences (Group)
	Product	cancer drug
	Product 2	drug development

Record changed: 2020-10-12

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Norbert Bischofberger

[1] Kronos Bio, Inc.. (8/19/20). "Press Release: Kronos Bio Appoints Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development". San Mateo, CA & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)